Dr. Bryan M. Davis, M.D.
ENT (Otolaryngology) (Otolaryngology Physician)
3030 N Circle Dr, Ste 300
Colorado Springs, CO 80909
Who else practices at this address →
El Paso County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 284
Licensed in Colorado since 2006, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Texas Medical School at Houston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Otolaryngology Physician primary
CO license DR-44924 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Centura Health-Penrose St Francis Health Services Colorado Springs, CO
Medical groups
- Colorado Otolaryngology Associates, LLC (21 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 284
- Services billed
- 788
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 227 | 158 |
| New patient office or other outpatient visit, 30-44 minutes | 135 | 135 |
| Test to assess middle ear function | 76 | 74 |
| Comprehensive hearing and speech recognition test | 74 | 73 |
| Exam of ear using a microscope | 71 | 53 |
| Established patient office or other outpatient visit, 30-39 minutes | 65 | 57 |
| New patient office or other outpatient visit, 45-59 minutes | 55 | 55 |
| Diagnostic exam of voice box using a flexible endoscope | 50 | 45 |
| Diagnostic exam of nasal passages using an endoscope | 48 | 45 |
| Control of bleeding of nose using an endoscope | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $229 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $194 |
|---|---|
| Lilly USA, LLC | $19.92 |
| Genzyme Corporation | $15.17 |
| Food and Beverage | $229 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $815,916 in research payments for these studies, mostly to the institutions running them.
- A phase 3, 24-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - CTP 1938 BIOKLEAR
Aerin Medical Inc. - A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Eli Lilly and Company · Recruiting · NCT06338995 - Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Paratek Pharmaceuticals, Inc. · Recruiting · NCT06850805 - A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.